Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,163
  • Shares Outstanding, K 45,279
  • Annual Sales, $ 23,070 K
  • Annual Income, $ -53,690 K
  • 60-Month Beta 2.51
  • Price/Sales 0.53
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/16/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.41 +7.11%
on 02/26/20
0.66 -34.23%
on 01/30/20
-0.20 (-31.76%)
since 01/24/20
3-Month
0.41 +7.11%
on 02/26/20
0.73 -40.54%
on 01/08/20
-0.21 (-32.49%)
since 11/26/19
52-Week
0.41 +7.11%
on 02/26/20
1.72 -74.77%
on 03/04/19
-1.19 (-73.21%)
since 02/26/19

Most Recent Stories

More News
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion

Clinical Data Intended to be Used to Support Pediatric Label Expansion for IXINITY

APVO : 0.44 (-2.22%)
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead...

AGIO : 48.37 (+3.55%)
ALXN : 94.56 (-1.64%)
ALPMF : 16.0700 (-5.58%)
CELGZ : 0.47 (+2.15%)
GILD : 74.94 (+6.90%)
APVO : 0.44 (-2.22%)
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA)...

APVO : 0.44 (-2.22%)
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

APVO : 0.44 (-2.22%)
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology...

APVO : 0.44 (-2.22%)
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing

APVO : 0.44 (-2.22%)
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

Reports Record Net Revenue for IXINITY;

APVO : 0.44 (-2.22%)
Aptevo Therapeutics Provides Corporate and Pipeline Update

Reports Record Quarterly IXINITY Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay

APVO : 0.44 (-2.22%)
Aptevo Therapeutics Introduces New Adaptir(TM) Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific

APVO : 0.44 (-2.22%)
Technological Advancements Aid Medical Practitioners in Combatting Cancer

In 2018, there was an estimated 1.73 million new cancer cases diagnosed and 609,640 cancer deaths in the U.S., according to the American Cancer Society. The ACS does not expect cancer rates to slow down...

ONPH : 0.0195 (-13.33%)
UEEC : 0.9900 (-2.94%)
AVEO : 4.85 (-1.02%)
APVO : 0.44 (-2.22%)
SLS : 2.64 (+27.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 0.52
1st Resistance Point 0.48
Last Price 0.44
1st Support Level 0.41
2nd Support Level 0.38

See More

52-Week High 1.72
Fibonacci 61.8% 1.22
Fibonacci 50% 1.06
Fibonacci 38.2% 0.91
Last Price 0.44
52-Week Low 0.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar